Use of sustained release dexamethasone in post-cataract surgery inflammation
View Patent ↗The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
1. A method of treating inflammation of an eye following cataract surgery comprising the steps of:
following completion of cataract surgery on the eye, administering by injecting into the eye a single dose of about 4 μL to about 6 μL of a formulation consisting essentially of about 517 μg dexamethasone in triethyl acetyl citrate;
wherein said formulation releases said dexamethasone for at least 3 days as measured in saline solution under infinite sink conditions.
2. The method of claim 1 , wherein the volume of said dose is about 5 μL.
3. The method of claim 1 , wherein said formulation releases said dexamethasone for at least 7 days, as measured in saline solution under infinite sink conditions.
4. The method of claim 1 , wherein said formulation releases said dexamethasone for at least 7 days, but no more than 35 days, as measured in saline solution under infinite sink conditions.
5. The method of claim 1 , wherein said formulation retains at least 30% of said dexamethasone after 3 days, as measured in saline solution under infinite sink conditions.
6. The method of claim 1 , wherein said single dose results in an anterior chamber cell count below 3 within 8 days of administration, when assessed by slit lamp microscopy.
7. The method of claim 1 , wherein said single dose results in an anterior chamber cell count below 2 within 30 days of administration when assessed by slit lamp microscopy.
8. The method of claim 1 , wherein said dose is injected behind the iris of the eye.
9. The method of claim 1 , wherein said dose is injected into the anterior segment of the eye.
10. The method of claim 1 , wherein said dose is injected into the anterior chamber of the eye.
11. The method of claim 8 , wherein the volume of said dose is about 5 μL.